The investigation was conducted as a meta-epidemiologic analysis, a form of research that studies how features of clinical trials influence their results. Instead of asking whether a particular drug, procedure or intensive-care strategy works, the researchers asked whether the way researchers measured recovery might be linked to the size of the reported effect. They identified randomized controlled trials involving adults with moderate-to-severe traumatic brain injury who received an acute-phase intervention or concurrent control treatment and were assessed at six months using either GOS or GOSE. In total, 84 trials involving more than 20,000 participants met the eligibility criteria. Dichotomous outcome data—typically classifying participants as having a favorable or unfavorable functional result—were available from 78 trials, including 53 GOS observations and 26 GOSE observations.

The GOS is a five-level scale that summarizes global recovery after brain injury, ranging from death to good recovery. The GOSE expands the instrument to eight levels by dividing several GOS categories into more detailed subdivisions. For example, “moderate disability” and “good recovery” can each be separated into upper and lower levels. This added resolution is designed to detect clinically meaningful differences that may be invisible on the shorter scale. However, increasing the number of categories also introduces additional requirements. Assessors must distinguish more finely between levels of independence, social participation and functional limitation, while trial teams must use consistent interviews and scoring procedures. Small differences in how outcomes are elicited or classified may therefore influence the final statistical estimate.

The central comparison was expressed as a ratio of odds ratios, or ROR. An odds ratio above one generally indicates greater odds of a favorable outcome with treatment, depending on how the endpoint is defined. The ROR compares the treatment effect reported in one trial group with the effect reported in another. In this analysis, an ROR below one indicated that GOSE-based trials tended to produce smaller treatment-effect estimates than GOS-based trials. Before accounting for differences between studies, the ROR was 0.718, a result that suggested a statistically significant contrast. After adjustment for publication year, multicenter status, income setting, intervention class, endpoint role and sample size, the ROR moved toward the null value of one, reaching 0.880 with a 95% confidence interval from 0.679 to 1.140. The adjusted association was not statistically significant, with a p value of 0.326.

The pooled results nevertheless showed a clear numerical pattern. GOS-based trials produced an overall odds ratio of 1.47, with a 95% confidence interval from 1.27 to 1.69. GOSE-based trials produced an odds ratio of 1.07, with a 95% confidence interval from 0.90 to 1.27. In practical terms, the conventional-scale studies appeared to report substantially more favorable treatment effects, while the extended-scale studies were, on average, close to showing no clear benefit. Because the confidence interval for the adjusted ROR included one, the investigators emphasized that the difference could reflect characteristics of the trials rather than a direct causal effect of the outcome scale. The outcome instrument may be part of a larger network of factors involving study era, patient selection, intervention type, analytical choices and research quality.

The researchers performed several analyses to test whether the pattern was fragile. Across sensitivity, ordinal-subset and structural analyses, the ROR remained directionally below one, ranging from 0.669 to 0.886. This consistency suggests that the observed contrast was not confined to a single statistical specification or a narrow group of studies. At the same time, the variation across analyses illustrates why a meta-epidemiologic association must be interpreted cautiously. When different trials use different outcome measures, the scale is not randomly assigned. Investigators may choose GOSE because a study is newer, larger, more methodologically rigorous or designed around modern functional-outcome standards. These characteristics can overlap, making it difficult to isolate the independent influence of the scale itself.

One notable finding was that GOSE-based trials had lower risk of bias across several assessed domains. That observation complicates any simple interpretation that the extended scale merely suppresses treatment effects. If GOSE studies were generally conducted with stronger methods, their more conservative results could reflect better control of bias, more careful outcome ascertainment or more realistic estimates of benefit. Older GOS trials may have used less standardized interviews, broader investigator discretion or analytic practices that amplified apparent differences between treatment and control groups. The analysis also examined small-study effects, which can occur when smaller trials produce unusually large estimates because of random variation, selective reporting or publication processes. These checks did not eliminate the broader pattern.

The study further explored whether the statistical method used to analyze the outcome could explain the findings. In a within-trial negative-control analysis, the comparison between binary and ordinal estimators was close to null. This result is important because the GOSE is inherently ordinal: its categories contain ordered information, and methods that use the full ranking can be more statistically efficient than simply dividing participants into favorable and unfavorable groups. An ordinal analysis may detect shifts across several levels of disability even when the proportion above a single threshold changes little. The near-null negative-control result suggested that differences between binary and ordinal estimators alone were unlikely to account for the between-trial contrast. Instead, the researchers point toward broader differences in trial design, populations, intervention classes and outcome ascertainment.

The findings arrive as the field increasingly recognizes that functional recovery after traumatic brain injury cannot always be reduced to survival or a single favorable-outcome threshold. A patient who moves from severe disability to moderate disability may experience a major improvement in daily life, even if both outcomes fall on the same side of a binary cutoff. Conversely, a threshold can make a modest numerical shift appear decisive when participants cluster near the boundary. The GOSE was developed partly to capture these gradations, but its value depends on reliable interviewing, clear definitions and consistent handling of missing data. Differences in how assessors conduct structured interviews, whether they use patient and caregiver information, and how they resolve uncertain classifications may affect both the precision and direction of treatment estimates.

For evidence synthesis, the message is practical rather than revolutionary: researchers should not automatically assume that GOS and GOSE results are fully interchangeable. Meta-analyses combining trials that use both scales may benefit from scale-stratified sensitivity analyses, in which the results are calculated separately and then compared. Review authors should also record whether outcomes were binary or ordinal, whether assessments used structured interviews, how favorable outcomes were defined and whether the measure was a primary endpoint or a secondary analysis. Trial designers, meanwhile, should justify their choice of outcome scale in advance and standardize training, interview procedures and statistical plans. The study does not establish that GOS is inferior or that GOSE is universally superior. Instead, it highlights how a seemingly technical measurement decision can influence the apparent strength of evidence in a field where treatment effects are often modest and long-term recovery is highly variable.

The authors conclude that GOS-based trials yielded larger treatment-effect estimates than GOSE-based trials, but they caution against interpreting the relationship as causal. Residual confounding between trials remains possible, even after adjustment for several study characteristics. The analysis also depended on published reports, which may omit relevant outcome details or reflect selective publication. Still, the results offer a timely challenge to conventional evidence-synthesis habits. In traumatic brain injury research, the scale used to describe recovery is not merely a label attached to the endpoint; it shapes the resolution, classification and statistical behavior of the outcome. As future trials increasingly adopt detailed functional measures, transparent reporting and harmonized assessment procedures may determine whether the next generation of pooled analyses produces clearer answers—or simply combines different kinds of evidence under the same name.

Subject of Research: Outcome-scale differences in treatment-effect estimates from moderate-to-severe traumatic brain injury trials.

Article Title: A Meta-epidemiologic Analysis of Differences in Treatment-Effect Estimates According to Outcome Scale (GOS vs. GOSE) in Moderate-to-Severe Traumatic Brain Injury Trials

Article References: Raccagni, N. G., Dotti, M., Lightfoot, Y. A., et al. “A Meta-epidemiologic Analysis of Differences in Treatment-Effect Estimates According to Outcome Scale (GOS vs. GOSE) in Moderate-to-Severe Traumatic Brain Injury Trials.” Neurocritical Care (2026). Springer Nature.

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02634-9

Keywords: Traumatic brain injury, Glasgow Outcome Scale, Extended Glasgow Outcome Scale, meta-epidemiology, randomized controlled trials, outcome measurement, evidence synthesis, treatment effects, functional recovery

Traumatic brain injuries remain a critical public health issue worldwide, representing the leading cause of trauma-related death and long-term disability. They frequently result from falls, vehicular accidents, and blunt force trauma. Timely and appropriate care in specialized trauma centers can dramatically affect prognosis. The current study analyzed a comprehensive sample of 55,606 TBI patients hospitalized in Ontario between April 2009 and March 2020, providing an unprecedented scope for understanding admission patterns and demographic influences on treatment.

Among the total cohort, 39% were female, with a striking admission difference: only 26% of these female patients were admitted to specialized trauma centers, as opposed to 38% of the male patients. Notably, the study accounted for critical confounders such as patient age, injury severity, comorbid health conditions, and socioeconomic status, yet the sex-based disparity in admission persists, suggesting underlying systemic or clinical biases rather than differences in clinical presentation alone.

A deeper dive into the demographics reveals that female patients were, on average, significantly older than males, with a median age of 78 compared to 67 years. The older age among female patients was also accompanied by higher incidences of dementia and hypertension, which could complicate clinical assessment and influence triage decisions. Conversely, male patients were more likely to suffer from severe head trauma, with 33% experiencing severe injuries compared to 25% among females, a factor traditionally associated with higher prioritization for specialized care.

This sex-based discrepancy in trauma center admission may be partly attributable to the nature of the injuries themselves. Female TBI cases were more often linked to low-energy mechanisms, especially ground-level falls, which can be perceived as less urgent or severe in prehospital settings. Such perceptions could inadvertently result in lower triage priority, despite the considerable morbidity these injuries can cause in elderly females. This finding underscores the need to reevaluate triage criteria to better capture the nuanced risk profiles associated with different injury mechanisms.

The authors, including Dr. Natalia Angeloni of Sunnybrook Health Sciences Centre and the University of Toronto, emphasize the potential role of unconscious sex-related bias influencing clinical judgment. Such implicit biases may lead to differential recognition and interpretation of injury severity, thereby affecting admission decisions. The study draws attention to how ingrained perceptions about gender and injury mechanisms could shape crucial emergency care pathways in subtle but impactful ways.

Moreover, the research highlights a broader systemic issue: the underrepresentation of female patients in TBI research. This skew limits the clinical community’s understanding of how trauma manifests and progresses differently across sexes. Consequently, prevailing clinical guidelines and treatment algorithms may be less attuned to the needs of female TBI patients, perpetuating disparities in care and outcomes.

The authors call for targeted research to disentangle the complex interplay of sex, gender, and clinical decision-making in trauma care. They argue that Ontario’s trauma triage system currently suffers from notable inefficiencies, characterized by both overtriage and undertriage. This variability in care delivery points to a pressing need for more nuanced and standardized triage protocols that incorporate sex- and gender-specific considerations to optimize patient outcomes.

Implicit bias in clinical settings has been increasingly recognized across various medical conditions, from cardiovascular disease to pain management. The current study’s findings suggest that TBI care is not immune to these influences. Investigating the conscious and unconscious factors shaping clinician behavior will be key to developing interventions aimed at reducing sex-based disparities and improving equity in trauma care.

Furthermore, the researchers advocate for educational initiatives to heighten clinicians’ awareness of potential biases and enhance the objectivity of triage assessments. This approach, coupled with data-driven revisions to triage guidelines, could move the system toward a more equitable framework that accounts for differing presentations of injury severity across sexes.

The implications of these findings extend well beyond Ontario, holding relevance for trauma systems globally. As populations age and the incidence of falls and TBIs rises, ensuring equitable access to specialized trauma care for all patients will become increasingly critical. The study offers a wake-up call to healthcare providers and policymakers about the importance of sex-specific research and tailored care pathways.

In conclusion, this comprehensive population-based cohort study uncovers a troubling gender gap in specialized trauma center admissions for adults with TBI. It highlights the need for urgent reforms in emergency medical triage processes to mitigate implicit biases and improve outcomes for female patients. Moving forward, integrating sex and gender considerations into trauma care research and clinical guidelines will be essential for advancing health equity in one of the most critical areas of emergency medicine.

Subject of Research: People
Article Title: Differences in admission to trauma centres by sex among adults with traumatic brain injury: a population-based cohort study
News Publication Date: 15-Jun-2026
Web References: https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251721
References: 10.1503/cmaj.251721
Keywords: Traumatic injury, Brain injuries, Emergency medicine, Health care delivery, Medical facilities